Nippon India Pharma Fund · Regular · Growth
NAV
₹585.2465
as of 13 Nov 2026
Expense Ratio
1.84%
AUM
₹9,272 Cr
Lumpsum returns (CAGR)
- 1Y
- +13.11%
- 3Y
- +17.50%
- 5Y
- +14.23%
- Since Inception
- +19.88%
SIP returns (XIRR)
- 1Y
- +20.31%
- 3Y
- +12.80%
- 5Y
- +16.91%
- Since Inception
- +18.48%
What history actually did — last 10 years (Nov 2016 – Nov 2026)
A ₹5,000 monthly SIP for the last 10 years (Nov 2016 – Nov 2026)
Real NAV backtest
A ₹5,000 monthly SIP would be worth ₹15,20,607 today — ₹6,00,000 invested, 17.9% XIRR.
₹6,00,000
Invested
₹15,20,607
Value today
17.9%
XIRR (p.a.)
A ₹1,00,000 lumpsum, the last 10 years (Nov 2016 – Nov 2026)
Real NAV backtest
₹1,00,000 invested 10 years ago would be ₹4,23,015 today (15.5% CAGR).
A regular withdrawal plan (SWP)
Real NAV backtest
A ₹10,00,000 corpus withdrawing ₹5,000/month since Nov 2016 would still hold ₹27,09,544.
Fund vs Benchmark (TRI)
Same SIP, benchmark total-return index
The same SIP would be worth ₹15,20,607 in this fund vs ₹11,99,859 in the benchmark — outperformance of ₹3,20,748.
Buying the worst day
Real NAV backtest
₹1,00,000 invested on the worst market day of the last 10 years (Nov 2016 – Nov 2026) (22 Mar 2020) would be ₹4,48,903 today (4.49×).
Historical simulation using actual published NAVs for the stated period. Past performance may or may not be sustained in the future. Not investment advice.
Risk Metrics
Trailing 1 year, annualised0.39
Sharpe Ratio
+0.06
Alpha
0.59
Beta
0.39
Sortino
12.07%
Std Dev
-10.24%
Max Drawdown
Performance Comparison
Sectoral allocation
as of 30 Sept 2026- Pharmaceuticals & Biotechnology73.97%
- Healthcare Services20.27%
- Retailing2.53%
- Healthcare Equipment & Supplies0.54%
Each sector links to the mutual funds most exposed to it.
Thinking about Nippon India Pharma Fund · Regular · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Compare with Similar Funds
Fund Details
Available transactions
Portfolio holdings
portfolio shared with NIPPON INDIA PHARMA FUND - DIRECT Plan - IDCW Option
- 1Sun Pharmaceutical Industries Limited11.71%
- 2Divi'S Laboratories Limited7.10%
- 3Lupin Limited6.17%
- 4Cipla Limited6.01%
- 5Dr. Reddy'S Laboratories Limited5.45%
- 6Apollo Hospitals Enterprise Limited4.89%
- 7Mankind Pharma Limited4.38%
- 8Sai Life Sciences Limited3.92%
- 9Ajanta Pharma Limited3.61%
- 10Glaxosmithkline Pharmaceuticals Limited3.11%
What this fund does
Nippon India Pharma Fund · Regular · Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
Nippon India Pharma Fund · Regular · Growth is a Sectoral / Thematic mutual fund offered by Nippon India Mutual Fund. The fund has been operational for over 22 years. It manages assets worth ₹9,272 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against BSE HEALTHCARE TRI. The current expense ratio is 1.84%.